Inclusion Criteria:  Breast cancer (histopathological diagnosis of localized invasive carcinoma or in situ carcinoma of the breast) and documented germline pathogenic variants of TP53.  Exclusion Criteria:  Patients with only other types of breast cancer such as sarcoma and phyllodes tumor were excluded from the analysis.